Company profile: Lucid Diagnostics
1.1 - Company Overview
Company description
- Provider of non-invasive, office-based diagnostic solutions for detecting Barrett's esophagus and esophageal adenocarcinoma, including EsoGuard, a DNA test using targeted next-generation sequencing to detect abnormal esophageal cells, and EsoCheck, a non-endoscopic swallowable capsule device that collects esophageal cells for analysis.
Products and services
- EsoCheck: A non-endoscopic swallowable capsule device that collects esophageal cells for analysis, aiding detection of Barrett's esophagus and esophageal adenocarcinoma
- EsoGuard: A non-invasive DNA test that detects abnormal esophageal cells to identify Barrett's esophagus and esophageal adenocarcinoma using targeted next-generation sequencing, NGS-based
- Office-based diagnostic test for esophageal cancer biomarkers: A non-invasive test developed to detect biomarkers to esophageal cancer performed in medical offices, office-based
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Lucid Diagnostics
Adze Biotech
HQ: United States
Website
- Description: Provider of pre-clinical oncolytic immunotherapies for cancer, including a chimeric adenoviral platform for systemic delivery of immune-stimulatory transgenes and checkpoint inhibitors to distant and local tumors. Pipeline includes Adze-1.17, which selectively kills tumor cells and releases tumor-derived antigens; Adze-1.17-CD40L for malignant glioma; and Ad657, a recombinant adenovirus with intratumoral and systemic potential across broad malignancies and solid tumor indications.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Adze Biotech company profile →
Exelixis
HQ: United States
Website
- Description: Provider of therapies for cancer and other serious diseases, discovering, developing and commercializing small-molecule and biotherapeutic treatments. Marketed products include CABOMETYX (cabozantinib) and COTELLIC (cobimetinib); MINNEBRO (esaxerenone) is marketed in Japan by Daiichi Sankyo. Offers clinical trials, early access to investigational medicines, and collaborations to advance experimental molecules.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Exelixis company profile →
Avant Diagnostics
HQ: United States
Website
- Description: Provider of medical diagnostic technology specializing in large panel biomarker screening.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Avant Diagnostics company profile →
HistoSonics
HQ: United States
Website
- Description: Provider of non-invasive medical devices and technologies for interventional radiology and surgical robotics.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full HistoSonics company profile →
Agios
HQ: United States
Website
- Description: Provider of biopharmaceutical therapeutics focused on cancer metabolism, offering PYRUKYND (mitapivat), an approved therapy for adults with pyruvate kinase deficiency to treat hemolytic anemia; late-stage trials of mitapivat for thalassemia and sickle cell disease; AG-946, an early-stage PK activator; and patient access services including myAgios and a Global Managed Access Program.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Agios company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Lucid Diagnostics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Lucid Diagnostics
2.2 - Growth funds investing in similar companies to Lucid Diagnostics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Lucid Diagnostics
4.2 - Public trading comparable groups for Lucid Diagnostics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →